DK1453512T3 - Acetylenderivater med mGluR5 antagonistisk virkning - Google Patents

Acetylenderivater med mGluR5 antagonistisk virkning

Info

Publication number
DK1453512T3
DK1453512T3 DK02792867T DK02792867T DK1453512T3 DK 1453512 T3 DK1453512 T3 DK 1453512T3 DK 02792867 T DK02792867 T DK 02792867T DK 02792867 T DK02792867 T DK 02792867T DK 1453512 T3 DK1453512 T3 DK 1453512T3
Authority
DK
Denmark
Prior art keywords
antagonistic effect
acetylene derivatives
mglur5
mglur5 antagonistic
acetylene
Prior art date
Application number
DK02792867T
Other languages
English (en)
Inventor
Fabrizio Gasparini
Yves Auberson
Silvio Ofner
Kaspar Zimmermann
Terance W Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9926969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1453512(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1453512T3 publication Critical patent/DK1453512T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK02792867T 2001-12-04 2002-12-03 Acetylenderivater med mGluR5 antagonistisk virkning DK1453512T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128996.6A GB0128996D0 (en) 2001-12-04 2001-12-04 Organic compounds

Publications (1)

Publication Number Publication Date
DK1453512T3 true DK1453512T3 (da) 2006-08-28

Family

ID=9926969

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02792867T DK1453512T3 (da) 2001-12-04 2002-12-03 Acetylenderivater med mGluR5 antagonistisk virkning

Country Status (32)

Country Link
US (4) US7348353B2 (da)
EP (1) EP1453512B8 (da)
JP (2) JP4176020B2 (da)
KR (2) KR100980901B1 (da)
CN (2) CN100430059C (da)
AR (2) AR037682A1 (da)
AT (1) ATE327755T1 (da)
AU (1) AU2002358585B2 (da)
BR (1) BR0214666A (da)
CA (1) CA2466560C (da)
CO (1) CO5590929A2 (da)
CY (1) CY1105460T1 (da)
DE (1) DE60211944T2 (da)
DK (1) DK1453512T3 (da)
EC (1) ECSP045139A (da)
EG (1) EG24936A (da)
ES (1) ES2263842T3 (da)
GB (1) GB0128996D0 (da)
HK (1) HK1071510A1 (da)
HU (1) HU229429B1 (da)
IL (1) IL161990A0 (da)
MX (1) MXPA04005456A (da)
MY (1) MY137774A (da)
NO (1) NO327005B1 (da)
NZ (1) NZ533266A (da)
PE (1) PE20030640A1 (da)
PL (1) PL212996B1 (da)
PT (1) PT1453512E (da)
RU (1) RU2341515C2 (da)
TW (1) TWI328578B (da)
WO (1) WO2003047581A1 (da)
ZA (1) ZA200403713B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
MX2009002684A (es) * 2006-09-11 2009-06-05 Novartis Ag Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
NZ584856A (en) * 2007-10-12 2012-12-21 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of parkinson's disease
AU2012254934B2 (en) * 2007-10-12 2013-10-17 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CN102131503A (zh) * 2008-06-30 2011-07-20 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品
NZ590753A (en) * 2008-08-12 2012-06-29 Novartis Ag Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
JP2012533601A (ja) 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
KR20130100906A (ko) 2010-04-30 2013-09-12 노파르티스 아게 취약 ｘ 증후군 （ｆｘｓ） 치료에 유용한 예측용 마커
KR20130098181A (ko) 2010-06-24 2013-09-04 노파르티스 아게 1ｈ-퀴나졸린-2,4-디온의 용도
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2655326A1 (en) * 2010-12-20 2013-10-30 Novartis AG 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
US9067881B2 (en) 2011-01-24 2015-06-30 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
EP2667862A1 (en) 2011-01-27 2013-12-04 Novartis AG Use of nicotinic acetylcholine receptor alpha 7 activators
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
KR20140071405A (ko) 2011-09-07 2014-06-11 노파르티스 아게 광민감성 간질의 예방 또는 치료에 사용하기 위한 1h-퀴나졸린-2,4-디온의 용도
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
GB201215033D0 (en) 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives
CN105246485B (zh) 2013-01-15 2019-03-15 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂的应用
EP2945626B1 (en) 2013-01-15 2018-09-12 Novartis AG Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
JP6444996B2 (ja) 2013-06-12 2018-12-26 ノバルティス アーゲー 調節放出製剤
CN105669686B (zh) * 2014-11-19 2018-08-03 上海合全药业股份有限公司 一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法
US20200237721A1 (en) 2017-07-31 2020-07-30 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
WO2020157640A1 (en) 2019-01-29 2020-08-06 Novartis Ag The use of an mglur5 antagonist for treating opioid analgesic tolerance
BR112022025730A2 (pt) 2020-07-17 2023-01-24 Novartis Ag Uso de antagonistas de mglur5
EP4259126A1 (en) 2020-12-11 2023-10-18 Novartis AG Use of mglur5 antagonists for treating amphetamine addiction
US20240082215A1 (en) 2020-12-14 2024-03-14 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2741009A1 (de) * 1976-09-22 1978-03-23 Sandoz Ag 4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
DE2802833A1 (de) 1978-01-23 1979-07-26 Sandoz Ag 4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
US5264456A (en) * 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
KR100284382B1 (ko) 1995-08-22 2001-03-02 미즈노 마사루 아미드화합물 및 그의 용도
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6313071B1 (en) * 1998-06-04 2001-11-06 Kumiai Chemical Industry Co., Ltd. Phenylacetylene derivatives and agricultural/horticultural fungicides
RU2232017C2 (ru) 1998-10-02 2004-07-10 Новартис Аг Антагонисты метаботропных глутаматных рецепторов (mglur5) для лечения боли и состояния тревоги
BR0012175A (pt) 1999-07-06 2002-03-05 Lilly Co Eli Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
GB0007108D0 (en) 2000-03-23 2000-05-17 Novartis Ag Organic compounds
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
CA2430696C (en) * 2000-12-04 2009-01-27 F. Hoffmann-La Roche Ag Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
US7138404B2 (en) 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
CN1315806C (zh) 2001-12-04 2007-05-16 霍夫曼·拉罗奇有限公司 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors

Also Published As

Publication number Publication date
HU229429B1 (en) 2013-12-30
KR100959204B1 (ko) 2010-05-19
TWI328578B (en) 2010-08-11
HK1071510A1 (en) 2005-07-22
PT1453512E (pt) 2006-10-31
NZ533266A (en) 2005-02-25
US20130331568A1 (en) 2013-12-12
PL212996B1 (pl) 2012-12-31
CN100430059C (zh) 2008-11-05
PE20030640A1 (es) 2003-09-12
GB0128996D0 (en) 2002-01-23
AR037682A1 (es) 2004-12-01
US20120010263A1 (en) 2012-01-12
RU2004120781A (ru) 2006-01-10
HUP0402191A2 (hu) 2005-02-28
CN1592623A (zh) 2005-03-09
AR088921A2 (es) 2014-07-16
NO327005B1 (no) 2009-04-06
JP2005514381A (ja) 2005-05-19
MXPA04005456A (es) 2004-10-11
MY137774A (en) 2009-03-31
KR20100020044A (ko) 2010-02-19
NO20042673L (no) 2004-06-25
AU2002358585A1 (en) 2003-06-17
EP1453512B8 (en) 2006-07-19
CA2466560C (en) 2010-07-27
JP4176020B2 (ja) 2008-11-05
BR0214666A (pt) 2004-11-03
DE60211944D1 (de) 2006-07-06
TW200304910A (en) 2003-10-16
ATE327755T1 (de) 2006-06-15
US8536229B2 (en) 2013-09-17
JP2008303226A (ja) 2008-12-18
HUP0402191A3 (en) 2010-03-29
DE60211944T2 (de) 2007-05-16
CN101366714B (zh) 2014-09-17
US20080146647A1 (en) 2008-06-19
PL368739A1 (en) 2005-04-04
CY1105460T1 (el) 2010-04-28
EP1453512B1 (en) 2006-05-31
JP5036648B2 (ja) 2012-09-26
RU2341515C2 (ru) 2008-12-20
EG24936A (en) 2011-01-11
CA2466560A1 (en) 2003-06-12
IL161990A0 (en) 2005-11-20
US7348353B2 (en) 2008-03-25
CN101366714A (zh) 2009-02-18
ECSP045139A (es) 2004-07-23
WO2003047581A1 (en) 2003-06-12
ES2263842T3 (es) 2006-12-16
CO5590929A2 (es) 2005-12-30
US20050065191A1 (en) 2005-03-24
EP1453512A1 (en) 2004-09-08
KR100980901B1 (ko) 2010-09-07
KR20050044657A (ko) 2005-05-12
ZA200403713B (en) 2005-10-26
AU2002358585B2 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
DK1453512T3 (da) Acetylenderivater med mGluR5 antagonistisk virkning
ATE361281T1 (de) Substituierte phenylderivate
DK3808743T3 (da) HIV-hæmmende pyrimidin-derivater
NO20034439L (no) Benzamidinderivater
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
ATE430129T1 (de) Substituierte thioacetamide
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE423771T1 (de) Tetrahydrochinolinderivate
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE60212694D1 (de) Benzothiazolderivaten
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATE346045T1 (de) Heteroaryl-substituierte aminocyclohexan-derivate
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
IS6468A (is) Heterósýklískar amíð afleiður
DE60202381D1 (de) Paroxetin-n-formyl-derivate